Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

DOBUTamine Hydrochloride in Dextrose

×

Overview

What is DOBUTamine Hydrochloride in Dextrose?

Dobutamine in 5% Dextrose Injection, USP is a sterile, nonpyrogenic, prediluted solution of dobutamine hydrochloride and dextrose in water for injection. It is administered by intravenous infusion.

Each 100 mL contains dobutamine hydrochloride equivalent to 100 mg, 200 mg, or 400 mg of dobutamine; dextrose (derived from corn), hydrous 5 g in water for injection, with sodium metabisulfite 25 mg and edetate disodium, dihydrate 10 mg added as stabilizers; osmolar concentration, respectively, 263, 270, or 284 mOsmol/liter (calc.). The pH is 3.0 (2.5 to 5.5). May contain hydrochloric acid and/or sodium hydroxide for pH adjustment. Dobutamine in 5% Dextrose Injection, USP is oxygen sensitive.

Dobutamine Hydrochloride, USP is chemically designated (±)-4-[2-[[3-(p-hydroxyphenyl)-1-methylpropyl]amino]ethyl]-pyrocatechol hydrochloride. It is a synthetic catecholamine.

Dextrose, USP is chemically designated D-glucose monohydrate (CHO • HO), a hexose sugar freely soluble in water. It has the following structural formula:

Water for Injection, USP is chemically designated HO.

The flexible plastic container is fabricated from a specially formulated CR3 plastic material. Water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly. Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials. Exposure to temperatures above 25°C/77°F during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period.



What does DOBUTamine Hydrochloride in Dextrose look like?



What are the available doses of DOBUTamine Hydrochloride in Dextrose?

Sorry No records found.

What should I talk to my health care provider before I take DOBUTamine Hydrochloride in Dextrose?

Sorry No records found

How should I use DOBUTamine Hydrochloride in Dextrose?

Dobutamine in 5% Dextrose Injection, USP is indicated when parenteral therapy is necessary for inotropic support in the treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. Experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions.

Whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-AMP-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. In controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-AMP-dependent inotropes were consistently associated with increased risks of hospitalization and death. Patients with NYHA Class IV symptoms appeared to be at particular risk.

Recommended Dosage

Dobutamine in 5% Dextrose Injection, USP is administered intravenously through a suitable intravenous catheter or needle. A calibrated electronic infusion device is recommended for controlling the rate of flow in mL/hour or drops/minute. Infusion of dobutamine should be started at a low rate (0.5 to 1.0 µg/kg/min) and titrated at intervals of a few minutes, guided by the patient's response, including systemic blood pressure, urine flow, frequency of ectopic activity, heart rate, and (whenever possible) measurements of cardiac output, central venous pressure, and/or pulmonary capillary wedge pressure. In reported trials, the optimal infusion rates have varied from patient to patient, usually 2 to 20 µg/kg/min but sometimes slightly outside of this range. On rare occasions, infusion rates up to 40 µg/kg/min have been required to obtain the desired effect.

Rates of infusion in mL/hour for dobutamine hydrochloride concentrations of 500, 1,000, 2,000 and 4,000 mg/L may be calculated using the following formula:

                                                                                                 

Example calculations for infusion rates are as follows:

Example 1:

                            (mL/h) =                                                                                  500 (µg/mL)

Example 2:

                            (mL/h) =                                                                                2,000 (µg/mL)

This container system may be inappropriate for the dosage requirements of pediatric patients under 30 kg.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

Dobutamine in 5% Dextrose Injection, USP solutions may exhibit a pink color that, if present, will increase with time. This color change is due to slight oxidation of the drug, but there is no significant loss of potency.

Solutions containing dextrose should not be administered through the same administration set as blood, as this may result in pseudoagglutination or hemolysis.

Do not add supplementary medications to Dobutamine in 5% Dextrose Injection, USP. Do not administer Dobutamine in 5% Dextrose Injection, USP simultaneously with solutions containing sodium bicarbonate or strong alkaline solutions.

INSTRUCTIONS FOR USE

To Open

Tear outer wrap at notch and remove solution container. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually.

Preparation for Administration

(Use aseptic technique)

WARNING: Do not use flexible container in series connections.


What interacts with DOBUTamine Hydrochloride in Dextrose?

Dobutamine in 5% Dextrose Injection, USP is contraindicated in patients with idiopathic hypertrophic subaortic stenosis and in patients who have shown previous manifestations of hypersensitivity to dobutamine or any of its components.



What are the warnings of DOBUTamine Hydrochloride in Dextrose?

Visual DisturbanceDifficulties with accommodation and blurring of vision have been reported with stimulant treatment.

Increase in Heart Rate or Blood Pressure

Dobutamine hydrochloride may cause a marked increase in heart rate or blood pressure, especially systolic pressure. Approximately 10% of adult patients in clinical studies have had rate increases of 30 beats/minute or more, and about 7.5% have had a 50-mm Hg or greater increase in systolic pressure. Usually, reduction of dosage reverses these effects.

Because dobutamine facilitates atrioventricular conduction, patients with atrial fibrillation are at risk of developing rapid ventricular response. In patients who have atrial fibrillation with rapid ventricular response, a digitalis preparation should be used prior to institution of therapy with dobutamine. Patients with pre-existing hypertension appear to face an increased risk of developing an exaggerated pressure response.

Ectopic Activity

Dobutamine may precipitate or exacerbate ventricular ectopic activity, but it rarely has caused ventricular tachycardia.

Hypersensitivity

Reactions suggestive of hypersensitivity associated with administration of Dobutamine in 5% Dextrose Injection, USP, including skin rash, fever, eosinophilia, and bronchospasm, have been reported occasionally.

Dobutamine in 5% Dextrose Injection, USP contains sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes, in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.


What are the precautions of DOBUTamine Hydrochloride in Dextrose?

General

During the administration of dobutamine, as with any adrenergic agent, ECG and blood pressure should be continuously monitored. In addition, pulmonary wedge pressure and cardiac output should be monitored whenever possible to aid in the safe and effective infusion of Dobutamine in 5% Dextrose Injection, USP.

Hypovolemia should be corrected with suitable volume expanders before treatment with Dobutamine in 5% Dextrose Injection, USP is instituted.

Animal studies indicate that dobutamine may be ineffective if the patient has recently received a β-blocking drug. In such a case, the peripheral vascular resistance may increase.

No improvement may be observed in the presence of marked mechanical obstruction, such as severe valvular aortic stenosis.

Do not administer unless solution is clear and container is undamaged. Discard unused portion.

Usage Following Acute Myocardial Infarction:

Drug Interactions:

Carcinogenesis, Mutagenesis, Impairment of Fertility:

Pregnancy

Pregnancy Category B:

Pediatric Use:

Geriatric Use:


What are the side effects of DOBUTamine Hydrochloride in Dextrose?

Hypotension:

Reactions at Sites of Intravenous Infusion:

Miscellaneous Uncommon Effects:

Administration of dobutamine, like other catecholamines, has been associated with decreases in serum potassium concentrations, rarely to hypokalemic values (See ).


What should I look out for while using DOBUTamine Hydrochloride in Dextrose?

Dobutamine in 5% Dextrose Injection, USP is contraindicated in patients with idiopathic hypertrophic subaortic stenosis and in patients who have shown previous manifestations of hypersensitivity to dobutamine or any of its components.

Increase in Heart Rate or Blood Pressure

Dobutamine hydrochloride may cause a marked increase in heart rate or blood pressure, especially systolic pressure. Approximately 10% of adult patients in clinical studies have had rate increases of 30 beats/minute or more, and about 7.5% have had a 50-mm Hg or greater increase in systolic pressure. Usually, reduction of dosage reverses these effects.

Because dobutamine facilitates atrioventricular conduction, patients with atrial fibrillation are at risk of developing rapid ventricular response. In patients who have atrial fibrillation with rapid ventricular response, a digitalis preparation should be used prior to institution of therapy with dobutamine. Patients with pre-existing hypertension appear to face an increased risk of developing an exaggerated pressure response.

Ectopic Activity

Dobutamine may precipitate or exacerbate ventricular ectopic activity, but it rarely has caused ventricular tachycardia.

Hypersensitivity

Reactions suggestive of hypersensitivity associated with administration of Dobutamine in 5% Dextrose Injection, USP, including skin rash, fever, eosinophilia, and bronchospasm, have been reported occasionally.

Dobutamine in 5% Dextrose Injection, USP contains sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes, in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.


What might happen if I take too much DOBUTamine Hydrochloride in Dextrose?

Overdoses of dobutamine have been reported rarely. The following is provided to serve as a guide if such an overdose is encountered.

Signs and Symptoms:

If the product is ingested, unpredictable absorption may occur from the mouth and the gastrointestinal tract.

The initial actions to be taken in a dobutamine hydrochloride overdose are discontinuing administration, establishing an airway, and ensuring oxygenation and ventilation. Resuscitative measures should be initiated promptly. Severe ventricular tachyarrhythmias may be successfully treated with propranolol or lidocaine. Hypertension usually responds to a reduction in dose or discontinuation of therapy.

Protect the patient's airway and support ventilation and perfusion. If needed, meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc. Absorption of drugs from the gastrointestinal tract may be decreased by giving activated charcoal, which, in many cases, is more effective than emesis or lavage; consider charcoal instead of or in addition to gastric emptying. Repeated doses of charcoal over time may hasten elimination of some drugs that have been absorbed. Safeguard the patient's airway when employing gastric emptying or charcoal.

Forced diuresis, peritoneal dialysis, hemodialysis, or charcoal hemoperfusion have not been established as beneficial for an overdose of dobutamine hydrochloride.


How should I store and handle DOBUTamine Hydrochloride in Dextrose?

Store Megestrol acetate oral suspension, USP between 20° to 25°C (68° to 77° F) [see USP Controlled Room Temperature]. Dispense in a tight container. Protect from heat.DOBUTamine in 5% Dextrose Injection, USP is supplied in 250 and 500 mL LifeCare™ flexible containers as follows:NDC No. 0409-2346-32 – 250 mg DOBUTamine in 5% Dextrose Injection, USP 250 mLNDC No. 0409-2346-34 – 500 mg DOBUTamine in 5% Dextrose Injection, USP 500 mLNDC No. 0409-2347-32 – 500 mg DOBUTamine in 5% Dextrose Injection, USP 250 mLNDC No. 0409-3724-32 – 1000 mg DOBUTamine in 5% Dextrose Injection, USP 250 mLDo not freeze. Store at 20 to 25ºC (68 to 77ºF). [See USP Controlled Room Temperature.]Revised: 5/2016                                                                               EN-4336Hospira, Inc., Lake Forest, IL 60045 USA                                                                                       DOBUTamine in 5% Dextrose Injection, USP is supplied in 250 and 500 mL LifeCare™ flexible containers as follows:NDC No. 0409-2346-32 – 250 mg DOBUTamine in 5% Dextrose Injection, USP 250 mLNDC No. 0409-2346-34 – 500 mg DOBUTamine in 5% Dextrose Injection, USP 500 mLNDC No. 0409-2347-32 – 500 mg DOBUTamine in 5% Dextrose Injection, USP 250 mLNDC No. 0409-3724-32 – 1000 mg DOBUTamine in 5% Dextrose Injection, USP 250 mLDo not freeze. Store at 20 to 25ºC (68 to 77ºF). [See USP Controlled Room Temperature.]Revised: 5/2016                                                                               EN-4336Hospira, Inc., Lake Forest, IL 60045 USA                                                                                       DOBUTamine in 5% Dextrose Injection, USP is supplied in 250 and 500 mL LifeCare™ flexible containers as follows:NDC No. 0409-2346-32 – 250 mg DOBUTamine in 5% Dextrose Injection, USP 250 mLNDC No. 0409-2346-34 – 500 mg DOBUTamine in 5% Dextrose Injection, USP 500 mLNDC No. 0409-2347-32 – 500 mg DOBUTamine in 5% Dextrose Injection, USP 250 mLNDC No. 0409-3724-32 – 1000 mg DOBUTamine in 5% Dextrose Injection, USP 250 mLDo not freeze. Store at 20 to 25ºC (68 to 77ºF). [See USP Controlled Room Temperature.]Revised: 5/2016                                                                               EN-4336Hospira, Inc., Lake Forest, IL 60045 USA                                                                                       DOBUTamine in 5% Dextrose Injection, USP is supplied in 250 and 500 mL LifeCare™ flexible containers as follows:NDC No. 0409-2346-32 – 250 mg DOBUTamine in 5% Dextrose Injection, USP 250 mLNDC No. 0409-2346-34 – 500 mg DOBUTamine in 5% Dextrose Injection, USP 500 mLNDC No. 0409-2347-32 – 500 mg DOBUTamine in 5% Dextrose Injection, USP 250 mLNDC No. 0409-3724-32 – 1000 mg DOBUTamine in 5% Dextrose Injection, USP 250 mLDo not freeze. Store at 20 to 25ºC (68 to 77ºF). [See USP Controlled Room Temperature.]Revised: 5/2016                                                                               EN-4336Hospira, Inc., Lake Forest, IL 60045 USA                                                                                       DOBUTamine in 5% Dextrose Injection, USP is supplied in 250 and 500 mL LifeCare™ flexible containers as follows:NDC No. 0409-2346-32 – 250 mg DOBUTamine in 5% Dextrose Injection, USP 250 mLNDC No. 0409-2346-34 – 500 mg DOBUTamine in 5% Dextrose Injection, USP 500 mLNDC No. 0409-2347-32 – 500 mg DOBUTamine in 5% Dextrose Injection, USP 250 mLNDC No. 0409-3724-32 – 1000 mg DOBUTamine in 5% Dextrose Injection, USP 250 mLDo not freeze. Store at 20 to 25ºC (68 to 77ºF). [See USP Controlled Room Temperature.]Revised: 5/2016                                                                               EN-4336Hospira, Inc., Lake Forest, IL 60045 USA